{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:40:05Z","timestamp":1761561605855},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,1,12]],"date-time":"2012-01-12T00:00:00Z","timestamp":1326326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1479-5876-10-10","type":"journal-article","created":{"date-parts":[[2012,1,12]],"date-time":"2012-01-12T19:18:29Z","timestamp":1326395909000},"source":"Crossref","is-referenced-by-count":38,"title":["HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy"],"prefix":"10.1186","volume":"10","author":[{"given":"George","family":"Fountzilas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Valavanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassiliki","family":"Kotoula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia G","family":"Eleftheraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantine T","family":"Kalogeras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olympia","family":"Tzaida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Batistatou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Kronenwett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph M","family":"Wirtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattheos","family":"Bobos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Timotheadou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Soupos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Vlachodimitropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genovefa","family":"Polychronidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerasimos","family":"Aravantinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelos","family":"Koutras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Pectasides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petroula","family":"Arapantoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,12]]},"reference":[{"key":"972_CR1","doi-asserted-by":"crossref","unstructured":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717.","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"972_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/bmj.332.7534.161","volume":"332","author":"I Smith","year":"2006","unstructured":"Smith I, Chua S: Medical treatment of early breast cancer. III: chemotherapy. BMJ (Clinical research ed. 2006, 332: 161-162. 10.1136\/bmj.332.7534.161.","journal-title":"BMJ (Clinical research ed"},{"key":"972_CR3","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1200\/JCO.2005.02.5841","volume":"23","author":"JJ Doyle","year":"2005","unstructured":"Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL: Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005, 23: 8597-8605. 10.1200\/JCO.2005.02.5841.","journal-title":"J Clin Oncol"},{"key":"972_CR4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/jnci\/djk028","volume":"99","author":"D Hershman","year":"2007","unstructured":"Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. Journal of the National Cancer Institute. 2007, 99: 196-205. 10.1093\/jnci\/djk028.","journal-title":"Journal of the National Cancer Institute"},{"key":"972_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","volume":"14","author":"JS Ross","year":"2009","unstructured":"Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. The oncologist. 2009, 14: 320-368. 10.1634\/theoncologist.2008-0230.","journal-title":"The oncologist"},{"key":"972_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science (New York, NY. 1987, 235: 177-182. 10.1126\/science.3798106.","journal-title":"Science (New York, NY"},{"key":"972_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2174\/156800906778742497","volume":"6","author":"TA Jarvinen","year":"2006","unstructured":"Jarvinen TA, Liu ET: Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer. Current cancer drug targets. 2006, 6: 579-602. 10.2174\/156800906778742497.","journal-title":"Current cancer drug targets"},{"key":"972_CR8","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1056\/NEJMoa071167","volume":"357","author":"DF Hayes","year":"2007","unstructured":"Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN: HER2 and response to paclitaxel in node-positive breast cancer. The New England journal of medicine. 2007, 357: 1496-1506. 10.1056\/NEJMoa071167.","journal-title":"The New England journal of medicine"},{"key":"972_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djm252","volume":"100","author":"A Gennari","year":"2008","unstructured":"Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. Journal of the National Cancer Institute. 2008, 100: 14-20. 10.1093\/jnci\/djm252.","journal-title":"Journal of the National Cancer Institute"},{"key":"972_CR10","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1023\/A:1011669223035","volume":"12","author":"A Di Leo","year":"2001","unstructured":"Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, Michel J, Focan CH, Ries F, Gobert PH: HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol. 2001, 12: 1081-1089. 10.1023\/A:1011669223035.","journal-title":"Ann Oncol"},{"key":"972_CR11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/jnci\/djh198","volume":"96","author":"GE Konecny","year":"2004","unstructured":"Konecny GE, Thomssen C, Luck HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D: Her-2\/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. Journal of the National Cancer Institute. 2004, 96: 1141-1151. 10.1093\/jnci\/djh198.","journal-title":"Journal of the National Cancer Institute"},{"key":"972_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","volume":"70","author":"JJ Champoux","year":"2001","unstructured":"Champoux JJ: DNA topoisomerases: structure, function, and mechanism. Annual review of biochemistry. 2001, 70: 369-413. 10.1146\/annurev.biochem.70.1.369.","journal-title":"Annual review of biochemistry"},{"key":"972_CR13","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1126\/science.1127196","volume":"312","author":"BG Ju","year":"2006","unstructured":"Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, Rosenfeld MG: A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science (New York, NY. 2006, 312: 1798-1802. 10.1126\/science.1127196.","journal-title":"Science (New York, NY"},{"key":"972_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.humpath.2004.11.010","volume":"36","author":"DG Hicks","year":"2005","unstructured":"Hicks DG, Tubbs RR: Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Human pathology. 2005, 36: 250-261. 10.1016\/j.humpath.2004.11.010.","journal-title":"Human pathology"},{"key":"972_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00432-005-0683-y","volume":"131","author":"C Schindlbeck","year":"2005","unstructured":"Schindlbeck C, Janni W, Shabani N, Kornmeier A, Rack B, Rjosk D, Gerber B, Braun S, Sommer H, Friese K: Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?. Journal of cancer research and clinical oncology. 2005, 131: 539-546. 10.1007\/s00432-005-0683-y.","journal-title":"Journal of cancer research and clinical oncology"},{"key":"972_CR16","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.humpath.2007.04.011","volume":"38","author":"MB Lambros","year":"2007","unstructured":"Lambros MB, Natrajan R, Reis-Filho JS: Chromogenic and fluorescent in situ hybridization in breast cancer. Human pathology. 2007, 38: 1105-1122. 10.1016\/j.humpath.2007.04.011.","journal-title":"Human pathology"},{"key":"972_CR17","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/annonc\/mdi366","volume":"16","author":"G Fountzilas","year":"2005","unstructured":"Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, Papadimitriou C, Markopoulos C, Polychronis A, Kalofonos HP: Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2005, 16: 1762-1771. 10.1093\/annonc\/mdi366.","journal-title":"Ann Oncol"},{"key":"972_CR18","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1200\/JCO.2009.22.8361","volume":"27","author":"KI Pritchard","year":"2009","unstructured":"Pritchard KI: Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?. J Clin Oncol. 2009, 27: 3875-3876. 10.1200\/JCO.2009.22.8361.","journal-title":"J Clin Oncol"},{"key":"972_CR19","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/nm0798-844","volume":"4","author":"J Kononen","year":"1998","unstructured":"Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature medicine. 1998, 4: 844-847. 10.1038\/nm0798-844.","journal-title":"Nature medicine"},{"key":"972_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00022744-200203000-00001","volume":"10","author":"M Skacel","year":"2002","unstructured":"Skacel M, Skilton B, Pettay JD, Tubbs RR: Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data. Appl Immunohistochem Mol Morphol. 2002, 10: 1-6. 10.1097\/00022744-200203000-00001.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"972_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000207504","volume":"76","author":"C Christodoulou","year":"2009","unstructured":"Christodoulou C, Kostopoulos I, Kalofonos HP, Lianos E, Bobos M, Briasoulis E, Gogas H, Razis E, Skarlos DV, Fountzilas G: Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Oncology. 2009, 76: 275-285. 10.1159\/000207504.","journal-title":"Oncology"},{"key":"972_CR22","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0002-9440(10)64785-2","volume":"157","author":"M Tanner","year":"2000","unstructured":"Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, Isola J: Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2\/neu oncogene amplification in archival breast cancer samples. The American journal of pathology. 2000, 157: 1467-1472. 10.1016\/S0002-9440(10)64785-2.","journal-title":"The American journal of pathology"},{"key":"972_CR23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","volume":"131","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A: American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Archives of pathology & laboratory medicine. 2007, 131: 18-43.","journal-title":"Archives of pathology & laboratory medicine"},{"key":"972_CR24","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1373\/clinchem.2008.122572","volume":"55","author":"K Bohmann","year":"2009","unstructured":"Bohmann K, Hennig G, Rogel U, Poremba C, Mueller BM, Fritz P, Stoerkel S, Schaefer KL: RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. Clin Chem. 2009, 55: 1719-1727. 10.1373\/clinchem.2008.122572.","journal-title":"Clin Chem"},{"key":"972_CR25","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1373\/clinchem.2010.151233","volume":"56","author":"G Hennig","year":"2010","unstructured":"Hennig G, Gehrmann M, Stropp U, Brauch H, Fritz P, Eichelbaum M, Schwab M, Schroth W: Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clinical chemistry. 2010, 56: 1845-1853. 10.1373\/clinchem.2010.151233.","journal-title":"Clinical chemistry"},{"key":"972_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/PDM.0b013e3181e3630c","volume":"20","author":"BM Muller","year":"2011","unstructured":"Muller BM, Kronenwett R, Hennig G, Euting H, Weber K, Bohmann K, Weichert W, Altmann G, Roth C, Winzer KJ: Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol. 2011, 20: 1-10. 10.1097\/PDM.0b013e3181e3630c.","journal-title":"Diagn Mol Pathol"},{"key":"972_CR27","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1309\/PCFK8YTQPYWD534F","volume":"123","author":"R Bhargava","year":"2005","unstructured":"Bhargava R, Lal P, Chen B: HER-2\/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. American journal of clinical pathology. 2005, 123: 889-895. 10.1309\/PCFK8YTQPYWD534F.","journal-title":"American journal of clinical pathology"},{"key":"972_CR28","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/jnci\/djp082","volume":"101","author":"MC Cheang","year":"2009","unstructured":"Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute. 2009, 101: 736-750. 10.1093\/jnci\/djp082.","journal-title":"Journal of the National Cancer Institute"},{"key":"972_CR29","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M: American Society of Clinical Oncology\/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010, 28: 2784-2795. 10.1200\/JCO.2009.25.6529.","journal-title":"J Clin Oncol"},{"key":"972_CR30","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","volume":"25","author":"CA Hudis","year":"2007","unstructured":"Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007, 25: 2127-2132. 10.1200\/JCO.2006.10.3523.","journal-title":"J Clin Oncol"},{"key":"972_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10549-006-9242-8","volume":"100","author":"LM McShane","year":"2006","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast cancer research and treatment. 2006, 100: 229-235. 10.1007\/s10549-006-9242-8.","journal-title":"Breast cancer research and treatment"},{"key":"972_CR32","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1093\/jnci\/djp335","volume":"101","author":"RM Simon","year":"2009","unstructured":"Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. Journal of the National Cancer Institute. 2009, 101: 1446-1452. 10.1093\/jnci\/djp335.","journal-title":"Journal of the National Cancer Institute"},{"key":"972_CR33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.molonc.2009.11.001","volume":"4","author":"KV Nielsen","year":"2010","unstructured":"Nielsen KV, Muller S, Moller S, Schonau A, Balslev E, Knoop AS, Ejlertsen B: Aberrations of ERBB2 and TOP2A genes in breast cancer. Molecular oncology. 2010, 4: 161-168. 10.1016\/j.molonc.2009.11.001.","journal-title":"Molecular oncology"},{"key":"972_CR34","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1200\/JCO.2010.29.5071","volume":"28","author":"P De","year":"2010","unstructured":"De P, Smith BR, Leyland-Jones B: Human epidermal growth factor receptor 2 testing: where are we?. J Clin Oncol. 2010, 28: 4289-4292. 10.1200\/JCO.2010.29.5071.","journal-title":"J Clin Oncol"},{"key":"972_CR35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.humpath.2009.07.001","volume":"41","author":"SS Shah","year":"2010","unstructured":"Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, Chen B: Impact of American Society of Clinical Oncology\/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Human pathology. 2010, 41: 103-106. 10.1016\/j.humpath.2009.07.001.","journal-title":"Human pathology"},{"key":"972_CR36","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1158\/1078-0432.CCR-09-2471","volume":"16","author":"JC Brase","year":"2010","unstructured":"Brase JC, Schmidt M, Fischbach T, Sultmann H, Bojar H, Koelbl H, Hellwig B, Rahnenfuhrer J, Hengstler JG, Gehrmann MC: ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res. 2010, 16: 2391-2401. 10.1158\/1078-0432.CCR-09-2471.","journal-title":"Clin Cancer Res"},{"key":"972_CR37","doi-asserted-by":"publisher","first-page":"R68","DOI":"10.1186\/bcr1776","volume":"9","author":"M van de Vijver","year":"2007","unstructured":"van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Ruschoff J: Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Res. 2007, 9: R68-10.1186\/bcr1776.","journal-title":"Breast Cancer Res"},{"key":"972_CR38","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/modpathol.2009.136","volume":"23","author":"CB Moelans","year":"2010","unstructured":"Moelans CB, de Weger RA, van Blokland MT, van der Wall E, van Diest PJ: Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Mod Pathol. 2010, 23: 62-70. 10.1038\/modpathol.2009.136.","journal-title":"Mod Pathol"},{"key":"972_CR39","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S1470-2045(10)70006-1","volume":"11","author":"JM Bartlett","year":"2010","unstructured":"Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW: Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT\/BR9601). The lancet oncology. 2010, 11: 266-274. 10.1016\/S1470-2045(10)70006-1.","journal-title":"The lancet oncology"},{"key":"972_CR40","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/(SICI)1098-2264(199910)26:2<142::AID-GCC6>3.0.CO;2-B","volume":"26","author":"TA Jarvinen","year":"1999","unstructured":"Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J: Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes, chromosomes & cancer. 1999, 26: 142-150. 10.1002\/(SICI)1098-2264(199910)26:2<142::AID-GCC6>3.0.CO;2-B.","journal-title":"Genes, chromosomes & cancer"},{"key":"972_CR41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1756-8722-1-12","volume":"1","author":"L Usha","year":"2008","unstructured":"Usha L, Tabesh B, Morrison LE, Rao RD, Jacobson K, Zhu A, Basu S, Coon JS: Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts. Journal of hematology & oncology. 2008, 1: 12-10.1186\/1756-8722-1-12.","journal-title":"Journal of hematology & oncology"},{"key":"972_CR42","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1200\/JCO.2009.27.5644","volume":"29","author":"MF Press","year":"2011","unstructured":"Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M: Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol. 2011, 29: 859-867. 10.1200\/JCO.2009.27.5644.","journal-title":"J Clin Oncol"},{"key":"972_CR43","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0959-8049(02)00745-1","volume":"39","author":"K Park","year":"2003","unstructured":"Park K, Kim J, Lim S, Han S: Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer. 2003, 39: 631-634. 10.1016\/S0959-8049(02)00745-1.","journal-title":"Eur J Cancer"},{"key":"972_CR44","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/jnci\/djp067","volume":"101","author":"FP O'Malley","year":"2009","unstructured":"O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. Journal of the National Cancer Institute. 2009, 101: 644-650. 10.1093\/jnci\/djp067.","journal-title":"Journal of the National Cancer Institute"},{"key":"972_CR45","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.2009.24.1166","volume":"28","author":"B Ejlertsen","year":"2010","unstructured":"Ejlertsen B, Jensen MB, Nielsen KV, Balslev E, Rasmussen BB, Willemoe GL, Hertel PB, Knoop AS, Mouridsen HT, Brunner N: HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol. 2010, 28: 984-990. 10.1200\/JCO.2009.24.1166.","journal-title":"J Clin Oncol"},{"key":"972_CR46","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1200\/JCO.2010.31.2231","volume":"29","author":"C Desmedt","year":"2011","unstructured":"Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B: Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol. 2011, 29: 1578-1586. 10.1200\/JCO.2010.31.2231.","journal-title":"J Clin Oncol"},{"key":"972_CR47","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/modpathol.2009.78","volume":"22","author":"IT Yeh","year":"2009","unstructured":"Yeh IT, Martin MA, Robetorye RS, Bolla AR, McCaskill C, Shah RK, Gorre ME, Mohammed MS, Gunn SR: Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol. 2009, 22: 1169-1175. 10.1038\/modpathol.2009.78.","journal-title":"Mod Pathol"},{"key":"972_CR48","volume-title":"Critical reviews in oncology\/hematology","author":"CB Moelans","year":"2011","unstructured":"Moelans CB, de Weger RA, Van der Wall E, van Diest PJ: Current technologies for HER2 testing in breast cancer. Critical reviews in oncology\/hematology. 2011"},{"key":"972_CR49","first-page":"1061","volume":"8","author":"JS Coon","year":"2002","unstructured":"Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD: Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res. 2002, 8: 1061-1067.","journal-title":"Clin Cancer Res"},{"key":"972_CR50","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/gcc.20008","volume":"39","author":"RE Mueller","year":"2004","unstructured":"Mueller RE, Parkes RK, Andrulis I, O'Malley FP: Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes, chromosomes & cancer. 2004, 39: 288-297. 10.1002\/gcc.20008.","journal-title":"Genes, chromosomes & cancer"},{"key":"972_CR51","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.ajpath.2010.12.042","volume":"178","author":"A Romero","year":"2011","unstructured":"Romero A, Martin M, Cheang MC, Lopez Garcia-Asenjo JA, Oliva B, He X, de la Hoya M, Garcia Saenz JA, Arroyo Fernandez M, Diaz Rubio E: Assessment of Topoisomerase II alpha status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. The American journal of pathology. 2011, 178: 1453-1460. 10.1016\/j.ajpath.2010.12.042.","journal-title":"The American journal of pathology"},{"key":"972_CR52","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1038\/bjc.1996.286","volume":"73","author":"MI Sandri","year":"1996","unstructured":"Sandri MI, Hochhauser D, Ayton P, Camplejohn RC, Whitehouse R, Turley H, Gatter K, Hickson ID, Harris AL: Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. British journal of cancer. 1996, 73: 1518-1524. 10.1038\/bjc.1996.286.","journal-title":"British journal of cancer"},{"key":"972_CR53","doi-asserted-by":"publisher","first-page":"9127","DOI":"10.1128\/MCB.20.24.9127-9137.2000","volume":"20","author":"DW Stacey","year":"2000","unstructured":"Stacey DW, Hitomi M, Chen G: Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity. Molecular and cellular biology. 2000, 20: 9127-9137. 10.1128\/MCB.20.24.9127-9137.2000.","journal-title":"Molecular and cellular biology"},{"key":"972_CR54","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1093\/nar\/24.22.4464","volume":"24","author":"MI Sandri","year":"1996","unstructured":"Sandri MI, Isaacs RJ, Ongkeko WM, Harris AL, Hickson ID, Broggini M, Vikhanskaya F: p53 regulates the minimal promoter of the human topoisomerase IIalpha gene. Nucleic acids research. 1996, 24: 4464-4470. 10.1093\/nar\/24.22.4464.","journal-title":"Nucleic acids research"},{"key":"972_CR55","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1093\/nar\/gkp067","volume":"37","author":"M Stros","year":"2009","unstructured":"Stros M, Polanska E, Struncova S, Pospisilova S: HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalpha. Nucleic acids research. 2009, 37: 2070-2086. 10.1093\/nar\/gkp067.","journal-title":"Nucleic acids research"},{"key":"972_CR56","doi-asserted-by":"publisher","first-page":"38384","DOI":"10.1074\/jbc.M005298200","volume":"275","author":"PC Goswami","year":"2000","unstructured":"Goswami PC, Sheren J, Albee LD, Parsian A, Sim JE, Ridnour LA, Higashikubo R, Gius D, Hunt CR, Spitz DR: Cell cycle-coupled variation in topoisomerase IIalpha mRNA is regulated by the 3'-untranslated region. Possible role of redox-sensitive protein binding in mRNA accumulation. The Journal of biological chemistry. 2000, 275: 38384-38392.","journal-title":"The Journal of biological chemistry"},{"key":"972_CR57","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/bcr1618","volume":"8","author":"MJ Beresford","year":"2006","unstructured":"Beresford MJ, Wilson GD, Makris A: Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res. 2006, 8: 216-10.1186\/bcr1618.","journal-title":"Breast Cancer Res"},{"key":"972_CR58","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrc2608","volume":"9","author":"JL Nitiss","year":"2009","unstructured":"Nitiss JL: DNA topoisomerase II and its growing repertoire of biological functions. Nature reviews. 2009, 9: 327-337. 10.1038\/nrc2608.","journal-title":"Nature reviews"},{"key":"972_CR59","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1016\/j.ejca.2006.06.013","volume":"42","author":"E Arriola","year":"2006","unstructured":"Arriola E, Moreno A, Varela M, Serra JM, Falo C, Benito E, Escobedo AP: Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer. Eur J Cancer. 2006, 42: 2954-2960. 10.1016\/j.ejca.2006.06.013.","journal-title":"Eur J Cancer"},{"key":"972_CR60","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","volume":"11","author":"R Yerushalmi","year":"2010","unstructured":"Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA: Ki67 in breast cancer: prognostic and predictive potential. The lancet oncology. 2010, 11: 174-183. 10.1016\/S1470-2045(09)70262-1.","journal-title":"The lancet oncology"},{"key":"972_CR61","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10549-008-9964-x","volume":"113","author":"A Rody","year":"2009","unstructured":"Rody A, Karn T, Ruckhaberle E, Muller V, Gehrmann M, Solbach C, Ahr A, Gatje R, Holtrich U, Kaufmann M: Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast cancer research and treatment. 2009, 113: 457-466. 10.1007\/s10549-008-9964-x.","journal-title":"Breast cancer research and treatment"},{"key":"972_CR62","first-page":"201","volume":"24","author":"F Cardoso","year":"2004","unstructured":"Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy JY, Rouas G, Sotiriou C, Renard N, Richard V, Piccart MJ, Di Leo A: Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced\/metastatic breast cancer. International journal of oncology. 2004, 24: 201-209.","journal-title":"International journal of oncology"},{"key":"972_CR63","first-page":"338","volume":"9","author":"JL Nitiss","year":"2009","unstructured":"Nitiss JL: Targeting DNA topoisomerase II in cancer chemotherapy. Nature reviews. 2009, 9: 338-350.","journal-title":"Nature reviews"},{"key":"972_CR64","doi-asserted-by":"publisher","first-page":"7483","DOI":"10.1200\/JCO.2005.11.007","volume":"23","author":"AS Knoop","year":"2005","unstructured":"Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdottir K, Olsen KE, Mouridsen H, Ejlertsen B: retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol. 2005, 23: 7483-7490. 10.1200\/JCO.2005.11.007.","journal-title":"J Clin Oncol"},{"key":"972_CR65","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1158\/1078-0432.CCR-08-1878","volume":"15","author":"R Natrajan","year":"2009","unstructured":"Natrajan R, Lambros MB, Rodriguez-Pinilla SM, Moreno-Bueno G, Tan DS, Marchio C, Vatcheva R, Rayter S, Mahler-Araujo B, Fulford LG: Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res. 2009, 15: 2711-2722. 10.1158\/1078-0432.CCR-08-1878.","journal-title":"Clin Cancer Res"},{"key":"972_CR66","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.breast.2006.06.008","volume":"16","author":"A Rody","year":"2007","unstructured":"Rody A, Karn T, Gatje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhaberle E: Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast (Edinburgh, Scotland). 2007, 16: 86-93. 10.1016\/j.breast.2006.06.008.","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"972_CR67","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/sj.bjc.6604769","volume":"99","author":"AK Koutras","year":"2008","unstructured":"Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G: Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. British journal of cancer. 2008, 99: 1775-1785. 10.1038\/sj.bjc.6604769.","journal-title":"British journal of cancer"},{"key":"972_CR68","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1200\/JCO.2008.21.6887","volume":"27","author":"L Pusztai","year":"2009","unstructured":"Pusztai L, Jeong JH, Gong Y, Ross JS, Kim C, Paik S, Rouzier R, Andre F, Hortobagyi GN, Wolmark N, Symmans WF: Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009, 27: 4287-4292. 10.1200\/JCO.2008.21.6887.","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"972_CR69","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1158\/1078-0432.CCR-10-0079","volume":"16","author":"C Dumontet","year":"2010","unstructured":"Dumontet C, Krajewska M, Treilleux I, Mackey JR, Martin M, Rupin M, Lafanechere L, Reed JC: BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010, 16: 3988-3997. 10.1158\/1078-0432.CCR-10-0079.","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"972_CR70","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10549-010-1316-y","volume":"126","author":"A Noske","year":"2011","unstructured":"Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Muller BM, Steffen J, von Toerne C, Wirtz R, Baumann I: Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial ( NCT00544765 ). Breast cancer research and treatment. 2011, 126: 109-117. 10.1007\/s10549-010-1316-y.","journal-title":"Breast cancer research and treatment"},{"key":"972_CR71","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/annonc\/mdm059","volume":"18","author":"J Bergqvist","year":"2007","unstructured":"Bergqvist J, Ohd JF, Smeds J, Klaar S, Isola J, Nordgren H, Elmberger GP, Hellborg H, Bjohle J, Borg AL: Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. Ann Oncol. 2007, 18: 845-850. 10.1093\/annonc\/mdm059.","journal-title":"Ann Oncol"},{"key":"972_CR72","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1309\/1AKQDQ057PQT9AKX","volume":"129","author":"M Barberis","year":"2008","unstructured":"Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S: Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis. American journal of clinical pathology. 2008, 129: 563-570. 10.1309\/1AKQDQ057PQT9AKX.","journal-title":"American journal of clinical pathology"},{"key":"972_CR73","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1373\/clinchem.2006.076497","volume":"53","author":"M Cronin","year":"2007","unstructured":"Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, Jeong J, Wu J, Langone KC, Watson D: Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clinical chemistry. 2007, 53: 1084-1091. 10.1373\/clinchem.2006.076497.","journal-title":"Clinical chemistry"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-10-10.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1479-5876-10-10\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-10-10.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T22:05:18Z","timestamp":1640469918000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-10-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,12]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["972"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-10-10","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,12]]},"article-number":"10"}}